Cargando…

Counteracting survival functions of EBNA3C in Epstein-Barr virus (EBV)-driven lymphoproliferative diseases by combination of SAHA and bortezomib

Combination of suberoylanilide hydroxamic acid (SAHA) and bortezomib (SAHA/bortezomib) was shown to synergistically induce killing of lymphoblastoid cell lines (LCL) and Burkitt lymphoma (BL) of type III or Wp-restricted latency, both of which express EBNA3A, -3B and -3C proteins. We hypothesize tha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hui, Kwai Fung, Yeung, Po Ling, Tam, Kam Pui, Chiang, Alan Kwok Shing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5982749/ https://www.ncbi.nlm.nih.gov/pubmed/29861856 http://dx.doi.org/10.18632/oncotarget.25341

Ejemplares similares

Viral-Targeted Strategies Against EBV-Associated Lymphoproliferative Diseases
por: Hui, Kwai Fung, et al.
Publicado: (2019)

Therapeutic Strategies against Epstein-Barr Virus-Associated Cancers Using Proteasome Inhibitors
por: Hui, Kwai Fung, et al.
Publicado: (2017)

Opportunities to Target the Life Cycle of Epstein-Barr Virus (EBV) in EBV-Associated Lymphoproliferative Disorders
por: Dugan, James P., et al.
Publicado: (2019)

An Epstein-Barr virus-specific cytotoxic T cell epitope in EBV nuclear antigen 3 (EBNA 3)
Publicado: (1990)

The Epstein-Barr Virus EBNA1 Protein
por: Frappier, Lori
Publicado: (2012)

Intracellular Iron Chelation by a Novel Compound, C7, Reactivates Epstein–Barr Virus (EBV) Lytic Cycle via the ERK-Autophagy Axis in EBV-Positive Epithelial Cancers
por: Yiu, Stephanie Pei Tung, et al.
Publicado: (2018)

Identification of Novel Small Organic Compounds with Diverse Structures for the Induction of Epstein-Barr Virus (EBV) Lytic Cycle in EBV-Positive Epithelial Malignancies
por: Choi, Chung King, et al.
Publicado: (2015)

Epstein-Barr Virus (EBV)-Related Lymphoproliferative Disorders in Ataxia Telangiectasia: Does ATM Regulate EBV Life Cycle?
por: Tatfi, Moussab, et al.
Publicado: (2019)

Epstein-Barr Virus (EBV) Latent Protein EBNA3A Directly Targets and Silences the STK39 Gene in B Cells Infected by EBV
por: Bazot, Quentin, et al.
Publicado: (2018)

Lytic Induction Therapy against Epstein–Barr Virus-Associated Malignancies: Past, Present, and Future
por: Yiu, Stephanie Pei Tung, et al.
Publicado: (2020)

Counteracting Effects of Cellular Notch and Epstein-Barr Virus EBNA2: Implications for Stromal Effects on Virus-Host Interactions
por: Rowe, Martin, et al.
Publicado: (2014)

Molecular Screening for Epstein-Barr virus (EBV): Detection of Genomic EBNA-1, EBNA-2, LMP-1, LMP-2 Among Vietnamese Patients with Nasopharyngeal Brush Samples
por: Lao, Thuan Duc, et al.
Publicado: (2017)

Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man
Publicado: (1991)

Potential Cellular Functions of Epstein-Barr Nuclear Antigen 1 (EBNA1) of Epstein-Barr Virus
por: Smith, Danielle Westhoff, et al.
Publicado: (2013)

641. Limited Utility of Epstein-Barr Virus (EBV) Surveillance for Predicting Post-Transplant Lymphoproliferative Disorder in EBV Seropositive Adult Lung Transplant Recipients
por: Heldman, Madeleine R, et al.
Publicado: (2023)

Leflunomide/teriflunomide inhibit Epstein-Barr virus (EBV)-induced lymphoproliferative disease and lytic viral replication
por: Bilger, Andrea, et al.
Publicado: (2017)

Hydroa vacciniforme-like lymphoproliferative disorder (HV-LPD) is an Epstein-Barr virus (EBV) associated disease()()
por: Ordoñez-Parra, Juliana, et al.
Publicado: (2021)

Novel Patterns of the Epstein-Barr Nuclear Antigen (EBNA-1) V-Val Subtype in EBV-associated Nasopharyngeal Carcinoma from Vietnam
por: Thuan, LD, et al.
Publicado: (2019)

Carcinoma-risk variant of EBNA1 deregulates Epstein-Barr Virus episomal latency
por: Dheekollu, Jayaraju, et al.
Publicado: (2017)

Similarities between the Epstein-Barr Virus (EBV) Nuclear Protein EBNA1 and the Pioneer Transcription Factor FoxA: Is EBNA1 a “Bookmarking” Oncoprotein that Alters the Host Cell Epigenotype?
por: Niller, Hans Helmut, et al.
Publicado: (2012)

Autoimmune Lymphoproliferative Syndrome and Epstein-Barr Virus-Associated Lymphoma: An Adjunctive Diagnostic Role for Monitoring EBV Viremia?
por: Pace, Romina, et al.
Publicado: (2013)

Refractory Epstein-Barr Virus (EBV)-Related Post-transplant Lymphoproliferative Disease: Cure by Combined Brentuximab Vedotin and Allogeneic EBV-Specific T-Lymphocytes
por: Mika, Thomas, et al.
Publicado: (2019)

EBNA1-targeted inhibitors: Novel approaches for the treatment of Epstein-Barr virus-associated cancers
por: Jiang, Lijun, et al.
Publicado: (2018)

Correction: Carcinoma-risk variant of EBNA1 deregulates Epstein-Barr Virus episomal latency
por: Dheekollu, Jayaraju, et al.
Publicado: (2019)

Reactivation of Epstein–Barr virus by a dual-responsive fluorescent EBNA1-targeting agent with Zn(2+)-chelating function
por: Jiang, Lijun, et al.
Publicado: (2019)

Burkitt's lymphoma: differential killing of Epstein-Barr virus (EBV) (+) and EBV(-) Burkitt lymphoma cells in vitro and dose-dependent lytic induction by bortezomib in vivo
por: Dufresne, AL, et al.
Publicado: (2009)

Contributions of Epstein–Barr Nuclear Antigen 1 (EBNA1) to Cell Immortalization and Survival
por: Frappier, Lori
Publicado: (2012)

The Epstein-Barr virus EBNA1 protein modulates the alternative splicing of cellular genes
por: Boudreault, Simon, et al.
Publicado: (2019)

X‐linked lymphoproliferative syndrome associated with Epstein–Barr virus encephalitis and lymphoproliferative disorder
por: Mukai, Takeo, et al.
Publicado: (2023)

Characterization of Epstein-Barr virus (EBV)-infected cells in EBV-associated hemophagocytic lymphohistiocytosis in two patients with X-linked lymphoproliferative syndrome type 1 and type 2
por: Yang, Xi, et al.
Publicado: (2012)

Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease
por: Vickers, Mark A, et al.
Publicado: (2014)

Epstein-Barr Virus Genome Deletions in Epstein-Barr Virus-Positive T/NK Cell Lymphoproliferative Diseases
por: Wongwiwat, Wiyada, et al.
Publicado: (2022)

From Conventional to Next Generation Sequencing of Epstein-Barr Virus Genomes
por: Kwok, Hin, et al.
Publicado: (2016)

An EBNA3C-deleted Epstein-Barr virus (EBV) mutant causes B-cell lymphomas with delayed onset in a cord blood-humanized mouse model
por: Romero-Masters, James C., et al.
Publicado: (2018)

Modulation of alternative splicing during early infection of human primary B lymphocytes with Epstein-Barr virus (EBV): a novel function for the viral EBNA-LP protein
por: Manet, Evelyne, et al.
Publicado: (2021)

Epstein-Barr Virus (EBV)-Associated Haemophagocytic Syndrome
por: Torti, Lorenza, et al.
Publicado: (2012)

Epstein-Barr Virus (EBV)-associated Gastric Carcinoma
por: Iizasa, Hisashi, et al.
Publicado: (2012)

CAR-T Cells Targeting Epstein-Barr Virus gp350 Validated in a Humanized Mouse Model of EBV Infection and Lymphoproliferative Disease
por: Slabik, Constanze, et al.
Publicado: (2020)

Analysis of Post-Transplant Lymphoproliferative Disorder (PTLD) Outcomes with Epstein–Barr Virus (EBV) Assessments—A Single Tertiary Referral Center Experience and Review of Literature
por: Lau, Eric, et al.
Publicado: (2021)

Induction and progression of human lymphoproliferative lesions by Epstein-Barr virus.
por: Chappuis, B B, et al.
Publicado: (1990)

Cannot write session to /tmp/vufind_sessions/sess_ed0smbsl1nkijo96491b8ogh42